Immunoglobulin G: potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo.
Mice with cyclophosphamide-induced neutropenia were challenged with four immunotypes of Pseudomonas aeruginosa by contamination of a small dorsal surface wound. The infections were lethal; 100% of control animals (n = 80) treated only with albumin died. Administration of an immunoglobulin G intravenous preparation (IGIV) and/or therapy with tobramycin or azlocillin was begun 16 hr after challenge. Mortality among mice (n = 120) treated only with an antibiotic was 75.0%, while that among mice (n = 80) treated only with IGIV was 78.8%. Combination therapy with IGIV and an antibiotic (n = 120) resulted in mortality of 38.3%. The protection afforded by IGIV may have resulted in part from neutralization of exotoxin A, as mice treated with IGIV before challenge with exotoxin A were subject to lower mortality and had lower levels of serum aspartate and alanine aminotransferases than controls.
D036002:ADP Ribose Transferases; D000818:Animals; D001390:Azlocillin / Q000627:therapeutic use*; D001427:Bacterial Toxins; D003131:Combined Modality Therapy; D004357:Drug Synergism; D005098:Exotoxins / Q000037:antagonists & inhibitors*; D005260:Female; D007074:Immunoglobulin G / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D051379:Mice; D009503:Neutropenia / Q000150:complications; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D014031:Tobramycin / Q000627:therapeutic use*; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D001390:Azlocillin; D001427:Bacterial Toxins; D005098:Exotoxins; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D014031:Tobramycin; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A